Registered title, quoted from ClinicalTrials.gov
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 51 hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 51
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
- Study siteAffiliated Hospital of Hebei University河北大学附属医院ShijiazhuangHospital page
- Study siteAffiliated Hospital of Qingdao University青岛大学附属医院QingdaoHospital page
- Study siteAnhui Provincial Cancer Hospital安徽省肿瘤医院HefeiHospital page
- Study siteAnyang Tumor Hospital安阳市肿瘤医院AnyangHospital page
- Study siteChinese PLA General Hospital中国人民解放军总医院BeijingHospital page
- Study siteChongqing University Cancer Hospital重庆大学附属肿瘤医院ChongqingHospital page
- Study siteFirst Affiliated Hospital of Anhui Medical University安徽医科大学第一附属医院HefeiHospital page
- Study siteFirst Affiliated Hospital of Bengbu Medical University蚌埠医学院第一附属医院BengbuHospital page
- Study siteFirst Affiliated Hospital of Henan University of Science and Technology河南科技大学第一附属医院LuoyangHospital page
- Study siteFirst Affiliated Hospital of Jinzhou Medical University锦州医科大学附属第一医院BeijingHospital page
- Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
- Study siteFirst Affiliated Hospital of Xinxiang Medical University河南医药大学第一附属医院XinxiangHospital page
- Study siteFirst Affiliated Hospital of Zhengzhou University郑州大学第一附属医院ZhengzhouHospital page
- Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
- Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
- Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
- Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
- Study siteFujian Cancer Hospital福建省肿瘤医院FuzhouHospital page
- Study siteGuangxi Medical University Cancer Hospital广西医科大学附属肿瘤医院NanningHospital page
- Study siteGuizhou Provincial People's Hospital贵州省人民医院GuiyangHospital page
- Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
- Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
- Study siteHubei Cancer Hospital湖北省肿瘤医院WuhanHospital page
- Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
- Study siteLiaoning Cancer Hospital & Institute辽宁省肿瘤医院ShenyangHospital page
- Study siteLinyi Cancer Hospital临沂市肿瘤医院LinyiHospital page
- Study siteMeizhou People's Hospital梅州市人民医院MeizhouHospital page
- Study siteNanchang People's HospitalNanchangHospital page
- Study siteRenji Hospital上海交通大学医学院附属仁济医院ShanghaiHospital page
- Study siteRenmin Hospital of Wuhan University武汉大学人民医院WuhanHospital page
- Study siteSecond Affiliated Hospital of Fujian Medical University福建医科大学附属第二医院QuanzhouHospital page
- Study siteSecond Affiliated Hospital of Xi'an Jiaotong University西安交通大学第二附属医院Xi'anHospital page
- Study siteSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
- Study siteSecond Hospital of Dalian Medical University大连医科大学附属第二医院DalianHospital page
- Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
- Study siteShantou Central Hospital汕头市中心医院ShantouHospital page
- Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
- Study siteSir Run Run Shaw Hospital浙江大学医学院附属邵逸夫医院HangzhouHospital page
- Study siteSun Yat-sen Memorial Hospital中山大学孙逸仙纪念医院GuangzhouHospital page
- Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
- Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
- Study siteTongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page
- Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
- Study siteWeifang People's Hospital潍坊市人民医院WeifangHospital page
- Study siteWest China Hospital四川大学华西医院ChengduHospital page
- Study siteXuzhou Central Hospital徐州市中心医院XuzhouHospital page
- Study siteYantai Yuhuangding Hospital烟台毓璜顶医院YantaiHospital page
- Study siteYishui Central Hospital临沂市中心医院LinyiHospital page
- Study siteYunnan Cancer Hospital云南省肿瘤医院KunmingHospital page
- Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page
- Study siteZhongnan Hospital of Wuhan University武汉大学中南医院WuhanHospital page
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07673029, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Pathologically confirmed unresectable or metastatic HER2 positive breast cancer previously treated with trastuzumab and taxane
Inclusion criterion 2
Prior anti-HER2 ADC therapy.
Exclusion criterion 1
Unrecovered toxicity from prior anticancer therapy, defined as toxicity (except for alopecia) not recovered to ≤Grade 1 (NCI-CTCAE v5.0) or baseline.
Exclusion criterion 6
Eastern Cooperative Oncology Group (ECOG) performance status score is 0 or 1.
Inclusion criterion 3
Presence of at least one measurable lesion according to RECIST v1.1
Inclusion criterion 4
Multiple primary malignancies within 3 years, except for adequately resected non-melanoma skin cancer, curatively treated in situ tumor, or contralateral breast cancer
Exclusion criterion 4
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07673029, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Male or female adults ≥ 18 years at the time of voluntary signing of informed consent.
- Pathologically confirmed unresectable or metastatic HER2 positive breast cancer previously treated with trastuzumab and taxane
- Eastern Cooperative Oncology Group (ECOG) performance status score is 0 or 1.
- Presence of at least one measurable lesion according to RECIST v1.1
- Expected survival time ≥ 12 weeks.
- Patients must give informed consent to this study and voluntarily sign written informed consent form prior to the study NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Exclusion Criteria:
- Prior anti-HER2 ADC therapy.
- Previous history of interstitial lung disease/noninfectious pneumonitis/radiation pneumonitis requiring steroid therapy.
- Known serious hypersensitivity to the active ingredients of the study drug, inactive ingredients in the formulation, or other antibody drugs.
- Multiple primary malignancies within 3 years, except for adequately resected non-melanoma skin cancer, curatively treated in situ tumor, or contralateral breast cancer
- Uncontrolled infection requiring intravenous antibiotics, antiviral or antifungal agents, autoimmune disease requiring treatment, uncontrolled diabetes, hypertension, or other systemic disease that makes compliance with study procedures difficult
- Unrecovered toxicity from prior anticancer therapy, defined as toxicity (except for alopecia) not recovered to ≤Grade 1 (NCI-CTCAE v5.0) or baseline.
Quoted from ClinicalTrials.gov, NCT07673029, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07673029, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.